OrbiMed’s Humana HUM Stock Holding History

OrbiMed’s Portfolio HUM Stock Details HUM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,000	Closed	-$11.2M	–	134
2023 Q2	$11.2M	Buy	+25,000	New	+$12.6M	0.2%	84
2017 Q1	–	Sell	-100,000	Closed	-$20.4M	–	139
2016 Q4	$20.4M	Buy	+100,000	New	+$19.1M	0.26%	69

Other funds holding HUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

OrbiMed's HUM Position: Q1 2024 in Review

OrbiMed sold out of Humana (HUM) in Q1 2024, closing a stake of 109,900 shares — an estimated $50.3M sold.

OrbiMed first reported a position in HUM in Q1 2016 and held it in 28 quarters. The position peaked at $185M in Q2 2017. 1,030 funds tracked by Wall St. Rank hold HUM as of Q1 2024.

OrbiMed reported no remaining Humana position as of Q1 2024 after selling out during the quarter.
OrbiMed sold 109,900 Humana shares in Q1 2024, an estimated $50.3M.
OrbiMed first reported a position in Humana in Q1 2016 and held it in 28 quarters.
OrbiMed's Humana position peaked at $185M in Q2 2017.
1,030 funds tracked by Wall St. Rank held Humana as of Q1 2024.

Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.